A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488

Inclusion Criteria: * Participants who have completed their last visit in the core studies ML21530 and MA21488 and that might benefit from treatment using the study drug according to the investigator's evaluation * Absence of an AE or current or recent laboratory finding that would prevent the use of the 8 mg/kg dose of the tocilizumab * Receiving outpatient treatment * For women who are not postmenopausal and are not surgically sterile: agreement to use at least one adequate method of contraception Exclusion Criteria: * Participants who have prematurely discontinued the core studies ML21530 and MA21488 for any reason * MA21488 study participants who remained untreated with tocilizumab after it's discontinuation according to the treatment-free remission criteria of MA21488 study * Immunization with a live/attenuated vaccine since the last administration of the study drug in the core studies ML21530 and ML21488 * Diagnosis after the last visit of the study ML21530 or after the last visit of the study MA21488 of a rheumatic autoimmune disease other than RA, including systemic erythematous lupus (SEL), mixed connective tissue disease (MCTD), scleroderma and polymyositis, or a significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty's syndrome). Secondary Sjogren's Syndrome and/or nodulosis with RA are allowed * Diagnosis after the last visit of the core study ML21530 or of the study MA21488 of an inflammatory joint disease other than RA …